Athenex, Inc Last News: Athenex partner in China on go to launch TAEST therapy studies; shares up 2% Athenex (ATNX +2.1%) announces that commercialization partner Xiangxue Pharmaceutical Company's subsidiary Xiangxue Life Sciences has received regulatory sign-off in China to start registration studies of T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy (candidate TAEST16001) in patients with solid tumors that are HLA-A*02:01-positive and NY-ESO-1-positive.
In July 2018, the companies established a joint venture, Axis Therapeutics Limited, to develop the TAEST technology. --- Buy Limit - $11.30 Take Profit - $12.10 Stop Loss - $10.89 ------ Take Profit = +7.17% Stop Loss = -3.54%